



## Bioengineering in Vaccine Design and Delivery

Guest Editor:

**Prof. Dr. Massimo Zollo**

Department of Molecular  
Medicine and Medical  
Biotechnology, Federico II  
Faculty of Naples, 80138 Napoli,  
Italy

Deadline for manuscript  
submissions:

**closed (1 November 2025)**

### Message from the Guest Editor

Dear Colleagues,

During vaccine development, it is essential to improve delivery and manufacturing methods to reach the safe, effective, and cost-effective vaccine production criteria.

Advances in bioengineering have made it possible to control the physicochemical properties of the vaccines for faster synthesis, improve the antigen presentation to get more robust immunogenicity of vaccines, and obtain safer vaccine formulas.

Recent developments in vaccine delivery include the development of various polymeric particles as vaccine carriers due to their high biocompatibility and biodegradability. It is also shown that biodegradable hyaluronic cryogel mediates sustained antigen and adjuvant release, leading to a durable immune response. Proof of concept studies in vitro and in vivo will also be considered.

Virus-like particles as vaccine carriers efficiently elicit the immune response and offer improved safety, especially for immunocompromised or elderly patients.

Scientists working on different strategies to improve vaccine effectiveness, safety, or manufacturing using bioengineering technology are welcome to submit their work to this Special Issue by August 2024.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)